Smartest Doc
Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer
Anticancer Research, 07/27/2012
Clinical Article
Ditsch N et al. – Patients with inflammatory breast cancer (IBC) benefited not from dose–dense sequential chemotherapy (DD–CT) but from breast–conserving surgery after neoadjuvant chemotherapy.
Methods- Out of 668 randomised patients, 101 patients presented with IBC.
- Patients received epirubicin followed by paclitaxel every 2weeks (DD-CT) or simultaneously every 3weeks (CD-CT).
- No differences in pathological complete response rates were observed [odds ratio (OR)=1.27, p=0.33].
- Most patients were scheduled for mastectomy before starting therapy; however, in 21.7% breast-conserving surgery was performed.
- Disease-free survival rates [Hazard Ratio (HR)=0.65; p=0.597] and overall survival rates (HR=1.40; p=0.327) were similar for both treatment arms.
- Patients with breast-conserving surgery had a significantly better outcome than patients treated with mastectomy (disease-free survival: HR=0.41; p=0.034 and overall survival: HR=0.09; p=0.003).
